Sun Pharma pulls eleven eye-care products from Indian market
Sun Pharma has ordered retailers to stop selling and to remove eleven ophthalmic medicines after a July 17 directive.
Sun Pharma issued a directive on July 17 telling its distributors to halt distribution of eleven ophthalmic medicines and to retrieve any stock already in the market. The products affected include Depopred 2ml, Brinolar (BKC Free), Brinzotim Eye Drops 5ml (BKC Free), several Lotepred eye-drop formulations, and Nepalact variants such as OD, Z, Toba-F and E/D. The company’s distribution arm asked retailers to stop further supply and to withdraw existing supplies from the trade channel.
The notice w. No reason for the withdrawal was disclosed in the available information.
Why it matters
Consumers and pharmacies must remove these eye medicines, potentially affecting treatment options and supply chains.
In this story